非小细胞肺癌患者血清肿瘤标记物的联合检测及其临床意义

Clinical Significance of Serum Tumor Markers Level in Patients with NSCLC

目的 探讨血清肿瘤标记物联合检测在非小细胞肺癌 (NSCLC)的诊断、分型、病情估价和疗效中的作用。方法 分别采用生化比色定量法、化学发光法和ELISA法 ,序贯检测 98例不同TMN分期的NSCLC患者的血清TSGF、CEA、CYFRA2 1- 1水平。结果 各型肺癌早期TSGF水平皆升高 ,但应与急性炎症相鉴别 ;CEA、CYFRA2 1- 1水平分别在腺癌和鳞癌早期即可增高 ;3项指标皆明显增高时 ,往往提示病变广泛或已为晚期。结论 结合临床和其他辅助检查 ,血清TSGF、CEA、CYFRA2 1- 1联合检测对NSCLC的早期鉴别诊断、推测病理类型、指导治疗、监测复发、判断预后有较大意义。

Objective To investigate the role of tumor markers in the diagnosis, pathological classification, progression and therapeutic efficiency evaluation in patients with NSCLC.Methods Serum levels of TSGF, CEA and CYFRA21-1 in 98 patients with NSCLC in different TMN stages were determined with chromatometry, chemoluminescence and ELISA methods respectively.Results It was found that TSGF increased in the most patients with lung cancer in various stages as well as in patients with acute inflammation. Serum concentrations of CEA and CYFRA21-1 were higher in adenocarcinoma and squamous carcinoma respectively than that of other subtypes and increased with the progress of clinical stages.High serum levels of TSGF, CEA, CYFRA21-1 could be seen in patients with more advanced stages of NSCLC, which might indicate a heavy tumor burden.Conclusion A combined analysis of serum levels of TSGF, CEA, CYFRA21-1 in addition to other clinical and accessory examinations may contribute to the early diagnosis, pathological classification, recurrence monitoring and prognosis evaluation of NSCLC.